AU2015336463B2 - Compositions and methods for treating insomnia - Google Patents

Compositions and methods for treating insomnia Download PDF

Info

Publication number
AU2015336463B2
AU2015336463B2 AU2015336463A AU2015336463A AU2015336463B2 AU 2015336463 B2 AU2015336463 B2 AU 2015336463B2 AU 2015336463 A AU2015336463 A AU 2015336463A AU 2015336463 A AU2015336463 A AU 2015336463A AU 2015336463 B2 AU2015336463 B2 AU 2015336463B2
Authority
AU
Australia
Prior art keywords
compound
daily dose
dosage form
mean
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2015336463A
Other languages
English (en)
Other versions
AU2015336463A1 (en
Inventor
Yurie Akimoto
Margaret MOLINE
Gina Pastino
Nobuya Suzuki
Nobuo Yoshida
Yasuhiro Zaima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2015336463A1 publication Critical patent/AU2015336463A1/en
Application granted granted Critical
Publication of AU2015336463B2 publication Critical patent/AU2015336463B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2015336463A 2014-10-23 2015-10-21 Compositions and methods for treating insomnia Active 2036-07-16 AU2015336463B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
US62/067,443 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (2)

Publication Number Publication Date
AU2015336463A1 AU2015336463A1 (en) 2017-05-04
AU2015336463B2 true AU2015336463B2 (en) 2020-06-18

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015336463A Active 2036-07-16 AU2015336463B2 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Country Status (14)

Country Link
US (3) US10188652B2 (enExample)
EP (1) EP3209298B1 (enExample)
JP (1) JP6659681B2 (enExample)
KR (1) KR102444608B1 (enExample)
CN (1) CN107810006B (enExample)
AU (1) AU2015336463B2 (enExample)
BR (1) BR112017007063A2 (enExample)
CA (1) CA2964504C (enExample)
ES (1) ES2843952T3 (enExample)
IL (1) IL251759B (enExample)
MX (1) MX376164B (enExample)
RU (1) RU2703297C2 (enExample)
SG (2) SG10202007759RA (enExample)
WO (1) WO2016063995A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015336463B2 (en) 2014-10-23 2020-06-18 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
MX379318B (es) * 2016-05-12 2025-03-10 Eisai R&D Man Co Ltd Metodos para tratar trastornos de sueño de ritmo circadiano.
TWI855386B (zh) 2016-08-10 2024-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
US20220305012A1 (en) * 2019-06-26 2022-09-29 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
WO2021050219A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
EP4076463A1 (en) * 2019-12-20 2022-10-26 Eisai R&D Management Co., Ltd. Use of lemborexant for treating insomnia
CA3164198A1 (en) * 2020-01-16 2021-07-22 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
JP2023521492A (ja) 2020-04-19 2023-05-24 イドーシア ファーマシューティカルズ リミテッド ダリドレキサントの医学的用途
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN120076808A (zh) 2022-09-23 2025-05-30 卫材R&D管理有限公司 减少与神经退行性疾病相关的神经退行性变的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
WO1996034877A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
BRPI0515571A (pt) 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
MX2009002625A (es) 2006-09-11 2009-03-24 Glaxo Group Ltd Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas.
KR20090077051A (ko) 2006-09-29 2009-07-14 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.1.0]헥산 유도체
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
AU2008303975B2 (en) 2007-09-21 2013-05-16 Sanofi (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
WO2011098955A1 (en) * 2010-02-15 2011-08-18 Koninklijke Philips Electronics N.V. Mitigation of control channel interference
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
AU2015336463B2 (en) 2014-10-23 2020-06-18 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BETTICA, P. et al. "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist" Journal of Psychopharmacology (2012) Vol.26 No.8, pages 1058 to 1070 *

Also Published As

Publication number Publication date
AU2015336463A1 (en) 2017-05-04
CA2964504C (en) 2022-08-23
JP2017531683A (ja) 2017-10-26
MX376164B (es) 2025-03-07
KR102444608B1 (ko) 2022-09-20
CA2964504A1 (en) 2016-04-28
US10702529B2 (en) 2020-07-07
EP3209298B1 (en) 2020-12-02
BR112017007063A2 (pt) 2018-02-14
CN107810006A (zh) 2018-03-16
RU2017112308A3 (enExample) 2019-05-08
EP3209298A4 (en) 2018-06-20
IL251759A0 (en) 2017-06-29
MX2017004950A (es) 2018-01-16
EP3209298A1 (en) 2017-08-30
ES2843952T3 (es) 2021-07-21
US11026944B2 (en) 2021-06-08
JP6659681B2 (ja) 2020-03-04
SG11201703064WA (en) 2017-05-30
RU2703297C2 (ru) 2019-10-16
US10188652B2 (en) 2019-01-29
CN107810006B (zh) 2021-03-30
KR20170068478A (ko) 2017-06-19
RU2017112308A (ru) 2018-11-26
US20190201399A1 (en) 2019-07-04
WO2016063995A1 (en) 2016-04-28
US20170252342A1 (en) 2017-09-07
US20200268754A1 (en) 2020-08-27
SG10202007759RA (en) 2020-09-29
IL251759B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
US11026944B2 (en) Compositions and methods for treating insomnia
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
JP5914626B2 (ja) 徐放性アミノピリジン組成物の使用方法
US20220017465A1 (en) Formulations of t-type calcium channel modulators and methods of use thereof
JP2012229261A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
KR20190019044A (ko) 마진돌 ir/sr 다층 정제 및 그의 주의력 결핍/과잉행동 장애 (adhd)의 치료를 위한 용도
TW200916091A (en) Neramexane for the treatment of nystagmus
JP5226732B2 (ja) 催眠用圧縮成型製剤
WO2025068765A1 (en) Method of treating post-traumatic stress disorder
WO2025194118A1 (en) Formulations and methods for alleviating sleep disorders
KR101151342B1 (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법
KR20120103521A (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법
KR20130106023A (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: DAYVIGO LEMBOREXANT

Filing date: 20210716

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: DAYVIGO LEMBOREXANT

Filing date: 20210716